Qiagen N.V.
QIAGEN N.V. QIAGEN’s results for second quarter 2019 in line with outlook at CER, revised full-year 2019 outlook due to intended restructuring of China NGS partnership
QIAGEN N.V. / Key word(s): Change in Forecast Key word(s): China restructuring; revised outlook Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN’s results for second quarter 2019 in line with outlook at CER, revised full-year 2019 outlook due to intended restructuring of China NGS partnership Venlo, The Netherlands, July 24, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it achieved the outlook set for net sales growth and adjusted earnings per share at constant exchange rates (CER) for the second quarter of 2019. As a result of the intention to restructure its next-generation sequencing (NGS) partnership in China, QIAGEN now expects full-year 2019 net sales growth of approximately 5-6% CER (previously about 7-8% CER) and adjusted diluted EPS of approximately $1.42-1.44 CER per share (previously about $1.45-1.47 CER). For the third quarter of 2019, QIAGEN expects net sales to grow approximately 4-5% CER. Adjusted diluted EPS is expected to be about $0.35-0.36 CER per share. QIAGEN intends to restructure the current format of its NGS partnership in China due to the slower-than-expected uptake of invitro diagnostic clinical sequencing in this country. Sales from this partnership were planned to be approximately $30 million for full-year 2019, and weighted primarily to the second half of this year. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands ISIN: NL0012169213 Frankfurt Stock Exchange, Regulated Market (Prime Standard) Contacts QIAGEN N.V.: Corporate Communications John Gilardi, Tel: +49 2103 29 11711; ir@qiagen.com Thomas Theuringer, Tel: +49 2013 29 11826 pr@qiagen.com
24-Jul-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | QIAGEN N.V. |
Hulsterweg 82 | |
5912 PL Venlo | |
Netherlands | |
Phone: | +31 7735566 – 00 |
Fax: | +31 77 35566-58 |
E-mail: | qiagen@qiagen.com |
Internet: | www.qiagen.com |
ISIN: | NL0012169213 |
WKN: | A2DKCH |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
EQS News ID: | 846475 |
End of Announcement | DGAP News Service |